JOHN L. HIGGINS - 14 May 2024 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role: Director
Signature: /s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed
Issuer symbol: TECH
Transactions as of: 14 May 2024
Net transactions value: -$243,577
Form type: 4
Filing time: 16 May 2024, 16:17:52 UTC
Previous filing: 31 Jan 2024
Next filing: 21 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TECH	Common Stock	Options Exercise	$91,800	+4,000	+11%	$22.95	40,608	14 May 2024	Direct
transaction	TECH	Common Stock	Sale	$335,377	-4,000	-9.9%	$83.84	36,608	14 May 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TECH	Stock Options (Right to Buy)	Options Exercise	$0	-4,000	-25%	$0.000000	12,000	14 May 2024	Common Stock	4,000	$22.95	Direct
holding	TECH	Stock Options (Right to Buy)						17,040	14 May 2024	Common Stock	17,040	$21.84	Direct
holding	TECH	Stock Options (Right to Buy)						15,940	14 May 2024	Common Stock	15,940	$25.30	Direct
holding	TECH	Stock Options (Right to Buy)						12,500	14 May 2024	Common Stock	12,500	$31.26	Direct
holding	TECH	Stock Options (Right to Buy)						7,592	14 May 2024	Common Stock	7,592	$44.96	Direct
holding	TECH	Stock Options (Right to Buy)						8,044	14 May 2024	Common Stock	8,044	$50.41	Direct
holding	TECH	Stock Options (Right to Buy)						6,028	14 May 2024	Common Stock	6,028	$63.92	Direct
holding	TECH	Stock Options (Right to Buy)						2,532	14 May 2024	Common Stock	2,532	$128.81	Direct
holding	TECH	Stock Options (Right to Buy)						3,460	14 May 2024	Common Stock	3,460	$73.94	Direct
holding	TECH	Stock Options (Right to Buy)						3,937	14 May 2024	Common Stock	3,937	$61.51	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 83.55 to 83.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 83.55 to 83.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders.